A Mayo Clinic team proposes a formal classification system called 'senotypes' to organize the profound heterogeneity of senescent cells across five dimensions: cell identity and context, inducing mechanism, temporal stage, multimodal molecular features, and physiological function. Rather than relying on single markers — a chronic weakness in the field — the framework anchors senotype classification in combinations of core hallmarks including durable cell-cycle arrest, altered secretory profiles (the SASP), macromolecular damage, and disrupted homeostasis.
This is a conceptual and organizational contribution, not an experimental discovery, yet its practical significance for longevity science is hard to overstate. Senescent cell accumulation is causally linked to age-related dysfunction across tissues, and senolytics (drugs that selectively eliminate senescent cells) have generated enormous clinical interest — yet trials have produced inconsistent results. A central reason: researchers have been treating senescent cells as a monolithic population, when they are profoundly context-dependent. A senescent hepatocyte driven by oncogene activation behaves nothing like a therapy-induced senescent fibroblast.
By formalizing senotypes as reference categories, this framework creates a common language enabling cross-study comparisons, better patient stratification in clinical trials, and more precise senotherapeutic targeting. The integration of single-cell transcriptomics, spatial proteomics, and computational methods makes rigorous senotype characterization now feasible. This is genuinely paradigm-organizing — not a paradigm shift, but the essential infrastructure that could make the senolytic therapeutic revolution actually deliver on its promise.
